CRNX - Conference and earnings call announcements

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.   Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on dis

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the C

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1×1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEU

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies Global Healthcare Conference 2025Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern TimeWebcast link: HERE The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Ph

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL. TD Cowen 45th Annual Healthcare Conference          Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time          Webcast link HERE Leerink Global Healthcare Conference           Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time          Webcast link HERE The live and archived webcasts will be accessible on the Events &

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time. To access the live webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crin

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Conference and the Evercore 7th Annual HealthCONx Conference are taking place in Miami, FL. Evercore 7th Annual HealthCONx Conference      Fireside chat on Tuesday, December 3, 2024 at 7:30 a.m. Eastern Time

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September. Morgan Stanley 22nd Annual Global Healthcare Conference Fireside chat on Wednesday, September 4, 2024 at 5:35 p.m. Eastern TimeWebcast link HERE Cantor Global Healthcare Conference Fireside chat on W

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024. Details of the corporate presentation are as follows: Date:Tuesday, January 9, 2024Time:3:45 p.m. Pacific TimeRoom:Borgia Room   The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1×1 meeting with management, please con

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6th Annual Evercore ISI HealthCONx Conference:Date: Tuesday, November 28, 2023Time: 3:50 p.m. Eastern Time Piper Sandler 35th Annual Healthcare Conference:Date: Thursday, November 30, 2023Time: 8:00 a.m. Eastern Time The live and archived webcast of both fireside chats will be accessible on the Events & Presentations page in th

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023Time: 1:00 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics' website at www.crinetics.com/events. If you are interested in arranging a 1×1 meeting with management, please contact your Cantor representative. About Crinet

Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 CRN04777 Development Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today reported financial results for the second quarter ended June 30, 2023. "The PATHFNDR program for acromegaly continues to progress as expected. Topline results from our Phase 3 PATHFNDR-1 study are expected in September and should provide insight into paltusotine's potential as an alternative to standard-of-care somatostatin rece

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs). In addition, the Crinetics management team will discuss its pipeline of internally discovered oral small molecule drug candidates, with a focus on the Phase 3 PATHFNDR-1 stud

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023. Details of the presentation are as follows: Date: Tuesday, February 14, 2023Time: 3:40 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the Investors section on the Crinetics' website at www.crinetics.com/events. About Crinetics PharmaceuticalsCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and c

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 – December 1, 2022. Details of the Crinetics fireside chat are as follows: Date & Time: November 30, 2022 at 1:00 PM (ET)Moderator: Josh Schimmer, Research Analyst, Evercore ISIWebcast Link: https://wsw.com/webcast/evercore29/crnx/2391810   The presentation may be accessed from the Evercore ISI platform or from the Events & Presentations page in the Investors section on the Company's website. A replay of the pres

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients. Topline results from the PATHFNDR-1 study are expected in the third quarter of 2023. The Phase 3 PATHFNDR-2 study's enrollment is ongoing and topline results are expected in the fourth quarter of 2023. If successful, Crinetics plans to submit data from the two studies to regulatory authorities in support of applications seeking approval for the use of paltusotine for

SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel. Details of the Crinetics presentation are as follows:Date & Time: Available on-demand beginning at 7:00 a.m. Eastern Time on Monday, September 12, 2022Webcast Link:https://journey.ct.events/view/876dc867-2584-4a20-a2fa-1c31a8c57fb8 The presentation may be accessed from the H.C. Wainwright platform or from the Events & Presentations page in the Investors section on the Comp

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in person in a fireside chat at the annual JMP Securities Life Sciences Conference, which is being held at the Lotte New York Palace on June 15-16, 2022. Details of the fireside chat are as follows:Date:Wednesday, June 15, 2022Time:3:30 p.m. Eastern TimeWebcast Link:https://wsw.com/webcast/jmp54/crnx/1693872 In addition, the live and archived presentation will be accessib

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022. Details of the presentation are as follows: Date:Wednesday, February 16, 2022Time:1:00 p.m. Eastern TimeWebcast Link:https://wsw.com/webcast/svbleerink67/crnx/2679350   In addition, the live and archived presentation will be accessible

SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that company management will participate in a fireside chat and one-on-one investor meetings at the 4th Annual Evercore ISI HealthCONx Conference, which is taking place virtually November 30, 2021 through December 2, 2021. Details on the fireside chat can be found below. Date:December 2, 2021Time:12:35 PM ETWebcast Link:https://wsw.com/webcast/evercore21/crnx/2381354 A webcast of the fireside chat will als

Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier Pipeline is Built from Crinetics' Core Nonpeptide Platform and Includes Drug Candidates and Leads Against 10 Oncology Targets Radionetics and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) --  Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel nonpeptide therapeutics for rare endocrine diseases and endocrine-related tumors, together with 5AM Ventures and Frazier Healthcare Partne

- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced its intent to develop a nonpeptide oral parathyroid hormone (PTH) receptor antagonist for the treatment of hypercalcemia associated with primary hyperparathyroidism (HPT) and other diseases of PTH receptor type 1 (PTHR1) over-activation. Details of the preclinical efforts supporting this newly disclosed program will be presented in a late-bre

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September: H.C. Wainwright: 23rd Annual Global Investment Conference (September 13-15, 2021): A pre-recorded company presentation by Dr. Scott Struthers, Founder & CEO, will be available on-demand for approximately 30 days beginning September 13, 2021 at 7:00 am ET. Company management will also be available for one-o

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a wide cross s

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today provided details of four presentations that were made at the Endocrine Society’s annual ENDO 2021 congress on the company’s product pipeline. A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company’s development of CRN04894 and CRN04777. In addition, a summary of the previously announced ACROBAT Edge Phase 2 results as well as details of an improved table